Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNs - Adjuvant activity can be greatly improved by appropriate formulation of cytosine

ADVERTISEMENT

Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNs
Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).


BioPharm International Supplements


Acknowledgments

This work was supported in part by Grant 42387 from the Bill & Melinda Gates Foundation. The authors would like to thank Martin Freide, PhD, for helpful discussions regarding method development.

CHRISTOPHER B. FOX is the lead formulation engineer, TIMOTHY S. DUTILL is the process development specialist II, JAMES CHESKO is a senior scientist, STEVE G. REED is the head of research and development, and THOMAS S. VEDVICK is the director of process sciences, all at the Infections Disease Research Institute, Seattle, WA, 206.330.2527,
RYAN C. ANDERSON, formerly of the Infections Disease Research Institute, currently is the account consultant—northern California, at Chemical Abstracts Service, Columbus, OH.

References

1. Salem AK. CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies. Adv Drug Del Rev. 2009;61:193–4.

2. Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini, S, et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine. 2008;26:552–61.

3. Ott G, Singh M, Kazzaz J, Briones M, Soenawan E, Ugozzoli M, et al. A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. J Control Rel. 2002;79:1–5.

4. Ioannou XP, Gomis SM, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S. Safety and efficacy of CpG-containing oligodeoxynucleotides as immunological adjuvants in rabbits. Vaccine. 2003;21:4368–72.

5. Linghua Z, Xingshan T, Fengzhen Z. The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo. Int Immunopharm. 2006;6:1267–76.

6. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA. 1998;95:15553–8.

7. Singh M, Chesko J, Kazzaz J, Ugozolli M, Malyala P, O'Hagan D. Surface-charged poly(lactide-co-glycolide) microparticles as novel antigen delivery systems. In: Singh M, editor. Vaccine adjuvants and delivery systems. Hoboken, NJ: John Wiley & Sons; 2007. p. 223–48.

8. Krieg AM. WO/2004/005476, WIPO, Nucleic acid compositions for stimulating immune responses, Coley Pharmaceutical Group, Inc., 2004.

9. CpG ODN Information Sheet, Coley Pharmaceutical Group, 2006.

10. Hem SL, HogenEsch H. Aluminum-containing adjuvants: properties, formulation, and use. In: Singh M, editor. Vaccine adjuvants and delivery systems. Hoboken, NJ: John Wiley & Sons; 2007. p. 81–114.

11. Lindblad EB. Aluminium adjuvants—in retrospect and prospect. Vaccine. 2004;22:3658–68.

12. Alhydrogel "85" 2% Certificate of Analysis. Brenntag Biosector. 2007.

13. Aebig JA, Mullen GED, Dobrescu G, Rausch K, Lamber L, Ajose-Popoola O, et al. Formulation of vaccines containing CpG oligonucleotides and alum. J Immunol Methods 2007;323:139–46.

14. Kritsch CE, Berger A, Heinrich-Cseh C, Bugajska-Schretter A, Zauner W. Separation and quantification of a novel two-component vaccine adjuvant. J Chromatogr B. 2005;822:263–70.

15. Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, van Nest G, Ott G, et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol. 1998;186:18–27.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here